World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
57
Citations
12520
World Ranking
13775
National Ranking
5829

Virginia F. Borges publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Virginia F. Borges sits on this spectrum.

47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 414 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 849 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 950 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 841 scientists 207–216 publications: 735 scientists 217–226 publications: 709 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 418 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 197 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 60 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientists 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientists 1,028+ publications: 100 scientists
47 publications 1,028+

This scientist: 380 publications — 88th percentile

88% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

Virginia F. Borges D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Virginia F. Borges sits on this spectrum.

40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 317 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 900 scientists 52–53 D-Index: 1,026 scientists 54–55 D-Index: 1,150 scientists 56–57 D-Index: 1,236 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,163 scientists 62–63 D-Index: 1,131 scientists 64–65 D-Index: 1,032 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 715 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 72 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40 D-Index 167+

This scientist: 57 D-Index — 31st percentile

31% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

Overview

Virginia F. Borges is affiliated with the University of Colorado Boulder in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a strong focus on oncology-related studies.

The scientist's main subfields of study include Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Genetics, and Public Health, Environmental and Occupational Health. Their research covers major topics such as Advanced Breast Cancer Therapies, Breast Cancer Treatment Studies, Cancer Risks and Factors, HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, Reproductive Biology and Fertility, and BRCA gene mutations in cancer.

Recent publications reflect Virginia F. Borges's focus on breast cancer and cancer therapies. Notable papers include:

  • Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial (2020, Journal of Clinical Oncology)
  • Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis (2021, Annals of Oncology)
  • Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer (2023, New England Journal of Medicine)
  • NRG-BR002: A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (2022, Journal of Clinical Oncology)
  • Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases (2022, JAMA Oncology)

Frequent co-authors in Virginia F. Borges's work include:

  • Ann H. Partridge
  • Kathryn J. Ruddy
  • Steven E. Come
  • Lidia Schapira
  • Shoshana M. Rosenberg

The scientist regularly publishes in several key venues, notably:

  • Cancer Research
  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • Annals of Oncology
  • npj Breast Cancer

This overview presents Virginia F. Borges as a researcher contributing extensively to breast cancer therapy and related oncological studies, with a significant body of work addressing clinical outcomes, treatment modalities, and cancer biology within a multidisciplinary context.

Best Publications

  • Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

    Rashmi K Murthy;Sherene Loi;Alicia Okines;Elisavet Paplomata

  • Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses.

    David Avigan;Baldev Vasir;Jianlin Gong;Virginia Borges

  • Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2

    Traci R. Lyons;Jenean O'Brien;Virginia F. Borges;Virginia F. Borges;Matthew W. Conklin

  • Preoperative Therapy With Trastuzumab and Paclitaxel Followed by Sequential Adjuvant Doxorubicin/Cyclophosphamide for HER2 Overexpressing Stage II or III Breast Cancer: A Pilot Study

    Harold J. Burstein;Lyndsay N. Harris;Rebecca Gelman;Susan C. Lester

  • Prospective Study of Fertility Concerns and Preservation Strategies in Young Women With Breast Cancer

    Kathryn J. Ruddy;Shari I. Gelber;Rulla M. Tamimi;Elizabeth S. Ginsburg

  • Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial

    Nancy U. Lin;Virginia Borges;Carey Anders;Rashmi K. Murthy

  • NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+

    Louis Fehrenbacher;Reena S. Cecchini;Charles E. Geyer;Priya Rastogi

  • Alternatively Activated Macrophages and Collagen Remodeling Characterize the Postpartum Involuting Mammary Gland across Species

    Jenean O'Brien;Traci Lyons;Jenifer Monks;M. Scott Lucia;M. Scott Lucia

  • Pregnancy and Breast Cancer: when They Collide

    Traci R. Lyons;Pepper J. Schedin;Virginia F. Borges

  • Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

    Peter F. Coccia;Alberto S. Pappo;Lynda Beaupin;Virginia F. Borges

  • Postpartum diagnosis demonstrates a high risk for metastasis and merits an expanded definition of pregnancy-associated breast cancer.

    Eryn B. Callihan;Dexiang Gao;Sonali Jindal;Traci R. Lyons

  • Parity, lactation, and breast cancer subtypes in African American women: results from the AMBER Consortium.

    Julie R. Palmer;Emma Viscidi;Melissa A. Troester;Melissa A. Troester;Chi Chen Hong

  • Microenvironment of the involuting mammary gland mediates mammary cancer progression.

    Pepper Schedin;Jenean O’Brien;Michael Rudolph;Torsten Stein

  • Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab.

    Richard P. Tobin;Kimberly R. Jordan;William A. Robinson;William A. Robinson;Dana Davis

  • Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study

    Rashmi Murthy;Virginia F Borges;Alison Conlin;Jorge Chaves

  • Wound healing-like immune program facilitates postpartum mammary gland involution and tumor progression.

    Holly A. Martinson;Sonali Jindal;Clarissa Durand-Rougely;Virginia F. Borges

  • Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients

    Kimberly R. Jordan;Rodabe N. Amaria;Oscar Ramirez;Eryn B. Callihan

  • Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC).

    Stacy L. Moulder;Virginia F. Borges;Tara Baetz;Tessa Mcspadden

  • Cyclooxygenase-2-dependent lymphangiogenesis promotes nodal metastasis of postpartum breast cancer.

    Traci R. Lyons;Virginia F. Borges;Virginia F. Borges;Courtney B. Betts;Qiuchen Guo

  • BRCA1 and BRCA2 mutation testing in young women with breast cancer

    Shoshana M. Rosenberg;Kathryn J. Ruddy;Rulla M. Tamimi;Shari Gelber

Frequent Co-Authors

Pepper Schedin
Pepper Schedin Oregon Health & Science University
Ann H. Partridge
Ann H. Partridge Harvard University
Rulla M. Tamimi
Rulla M. Tamimi Cornell University
Anthony D. Elias
Anthony D. Elias University of Colorado Boulder
Eric P. Winer
Eric P. Winer Yale University
Ian E. Krop
Ian E. Krop Harvard University
Sherene Loi
Sherene Loi Peter MacCallum Cancer Centre
Martin D. McCarter
Martin D. McCarter University of Colorado Anschutz Medical Campus
Lisa A. Carey
Lisa A. Carey University of North Carolina at Chapel Hill
Gabriel N. Hortobagyi
Gabriel N. Hortobagyi The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Biology and Biochemistry can open doors to many exciting and rewarding careers in healthcare and life sciences. As demand grows for specialized roles, online degree pathways make it easier than ever to transition into fast-growing fields. For example, accredited ultrasound tech school online programs allow students to enter medical imaging, while affordable online radiology programs prepare you for essential diagnostic work.

If you are interested in nutritional health and wellness, the best dietitian programs can help you qualify as a registered dietitian, offering services in hospitals, clinics, or through private practice. For those seeking entry into patient care, online medical assisting classes provide comprehensive training with flexible schedules and financial aid options.

Each of these online programs supports diverse interests within biology and healthcare, providing both flexibility and strong job prospects. Whether you plan a clinical, technical, or research-oriented career, online study options help make your professional goals more accessible.

Best Scientists Citing Virginia F. Borges

Trending Scientists

Recently Published Articles